Gilles Gallant, BPharm, PhD, FOPQ, is an oncology expert with broad biotechnology and pharmaceutical experience in strategic cancer drug development, evaluation and innovations. He joined Mythic Therapeutics (Waltham, Massachusetts) in 2022 as Chief Development Officer and led and directed the development organization, including clinical operations, clinical sciences, regulatory affairs, clinical quality, project leadership, project management, data management, biostatistics and drug safety, responsible for developing new, smarter and safer, innovative antibody-drug conjugates (ADCs). Prior to joining Mythic Therapeutics, Gilles was Senior Vice-President, Global Head, Oncology Development at Daiichi Sankyo. He led the development of the Daiichi Sankyo global oncology portfolio, including the clinical development and global approval of Enhertu® for multiple indications (breast cancer, gastric cancer, NSCLC), the progress of several novel ADCs and multiple other early and late clinical stage best-in-class (BIC) or first-in-class (FIC) oncology assets.